Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jaguar Health, Inc. filings document a commercial-stage pharmaceutical issuer with Nasdaq-listed common stock and a focus on plant-derived gastrointestinal medicines. Recent 8-K reports cover Nasdaq continued-listing standards, bid-price and publicly held share requirements, reverse-stock-split effects, pre-funded warrant exercises, stockholders' equity considerations, and material agreements involving Napo Pharmaceuticals.
Proxy and charter filings describe stockholder votes, amendments to the company's certificate of incorporation, authorized-share changes, and governance procedures. The company's regulatory record also includes disclosures on crofelemer programs, Mytesi, Canalevia-CA1, operating and financial results, capital structure, clinical or regulatory matters, and other material events affecting the human-health and animal-health businesses.
Lincoln Alternative Strategies LLC filed a Form 3 reporting initial beneficial ownership in Jaguar Health, Inc. (JAGX). The filing states the reporting person holds 600,000 shares of Common Stock as a direct owner. The filing identifies the reporting persons relationship to the issuer as a Director and 10% owner. The statement is dated 08/28/2025 with a signature dated 08/29/2025.
Lincoln Alternative Strategies LLC disclosed ownership of 600,000 shares of Jaguar Health, Inc., representing 18.92% of the outstanding common stock based on 3,171,566 shares as of August 28, 2025. The filing shows Lincoln holds sole voting and sole dispositive power over all 600,000 shares. The Schedule 13G lists the issuer's and filer’s addresses and identifies the filer as a Delaware entity. The filer also certifies the shares were not acquired to change or influence control of the issuer.
Jaguar Health, Inc. held its 2025 Annual Meeting of Stockholders on August 19, 2025, where all seven proposals put to a vote were approved. The proposals were previously described in the company’s proxy statement.
Stockholders elected three directors to the board: James J. Bochnowski received 359,092 votes for and 21,757 withheld, Lisa A. Conte received 357,147 votes for and 23,702 withheld, and Jonathan B. Siegel received 361,236 votes for and 19,613 withheld; each director election had 425,060 broker non-votes. One proposal received 778,506 votes for, 13,484 against, and 13,919 abstentions, while several others each received over 321,000 votes for with 425,060 broker non-votes. The company also issued a press release summarizing these results, furnished as an exhibit.
Jaguar Health, Inc. Schedule 13G/A discloses that CVI Investments, Inc. and Heights Capital Management, Inc. collectively report beneficial ownership of 147,000 shares, equal to 9.9% of the class. The filing states the reported shares consist of shares issuable upon exercise of warrants and that the warrants are not exercisable to the extent exercise would cause ownership to exceed 9.99%. The company's prospectus reported 1,324,471 shares outstanding (excluding shares underlying the warrants) as of June 13, 2025.
The filing shows shared voting and dispositive power of 147,000 shares and no sole voting or dispositive power. Heights Capital serves as investment manager to CVI and may be deemed to exercise voting and dispositive power over the shares; both reporting persons disclaim beneficial ownership except for their pecuniary interest. The statement is signed by Sarah Travis on 08/12/2025 and references previously filed Limited Power of Attorney and Joint Filing Agreement exhibits.
Jaguar Health, Inc. announced a Sixth Amendment to its At-The-Market (ATM) Offering Agreement that extends Lucid Capital Markets, LLC's role as a Manager under the agreement. The amendment extends Lucid's term retrospectively from June 30, 2025 to December 31, 2025, unless the parties agree to a further extension.
The amendment clarifies that if the agreement is not otherwise amended or extended, Ladenburg Thalmann & Co. Inc. will remain as the sole Manager after December 31, 2025. The company also filed a prospectus supplement (referencing the May 23, 2024 supplement and May 1, 2024 prospectus) relating to the amendment, and attached the full amendment as Exhibit 10.1.
Jaguar Health, Inc. filed Supplement No. 6 to its ATM Prospectus Supplement to amend the At-The-Market Offering Agreement with Ladenburg Thalmann and Lucid Capital Markets. The amendment, dated August 14, 2025, extends Lucid's role as a Manager under the ATM Agreement retrospectively from June 30, 2025 through December 31, 2025, unless further extended, after which Ladenburg would be the sole Manager.
Since the ATM Prospectus Supplement dated May 23, 2024, the company has sold 1,370,282 shares under the ATM Program for gross proceeds of approximately $22.9 million, leaving approximately $1.66 million available for future sales. The last reported Nasdaq sale price on August 13, 2025 was $2.59 per share.
Jaguar Health, Inc. reported total net revenue of $2.98 million for the quarter ended June 30, 2025 (product revenue $2.94M), up from $2.72M a year earlier, and $5.19 million for the six months ended June 30, 2025 versus $5.07M in 2024. Operating expenses rose to $11.0 million for the quarter, producing an operating loss of $8.01 million and a net loss of $10.56 million (six-month net loss $21.16 million).
On the balance sheet, cash fell to $2.21 million at June 30, 2025 from $8.00M at year-end; total assets were $48.27 million and total liabilities $41.39 million. The Company discloses an accumulated deficit of $367.35 million and states its current cash balances are not sufficient to fund its operating plan through one year, noting substantial doubt about continuing as a going concern. Financing during the six months provided $7.62M (including a $3.25M ATM and $3.45M of convertible notes). Revenue remains concentrated: two specialty pharmacy customers accounted for roughly ~88% of product revenue.